Profile data is unavailable for this security.
About the company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
- Revenue in USD (TTM)1.97bn
- Net income in USD341.30m
- Incorporated1996
- Employees5.97k
- LocationQiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
- Phone+31 773556600
- Fax+31 773208409
- Websitehttps://www.qiagen.com/
Holder | Shares | % Held |
---|---|---|
Massachusetts Financial Services Co.as of 29 Dec 2023 | 24.07m | 10.87% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 8.01m | 3.62% |
BlackRock Fund Advisorsas of 05 Apr 2024 | 7.45m | 3.37% |
Norges Bank Investment Managementas of 01 Apr 2024 | 6.53m | 2.95% |
MFS International (UK) Ltd.as of 31 Mar 2024 | 5.25m | 2.37% |
Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 4.35m | 1.96% |
MFS International Singapore Pte. Ltd.as of 31 Mar 2024 | 4.09m | 1.85% |
BlackRock Asset Management Deutschland AGas of 05 Apr 2024 | 2.86m | 1.29% |
Deka Investment GmbHas of 04 Apr 2024 | 2.80m | 1.27% |
BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 2.73m | 1.23% |